Saia Sprints Monday on Q4, FY Numbers
Saia, Inc. (NASDAQ: SAIA) shares jumped Monday, as the company, a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today reported fourth-quarter 2024 financial results. Diluted earnings per share for the quarter were $2.84 compared to $3.33 in the fourth quarter of 2023. Full year diluted earnings per share were $13.51 in 2024 compared to $13.26 in 2023.Highlights from the fourth-quarter and full-year operating results were as follows:Fourth Quarter 2024 Compared to Fourth Quarter 2023 Results• Revenue was $789.0 million, a 5.0% increase• Operating income was $101.5 million, a 9.9% decrease• Operating ratio of 87.1% compared to 85.0%• LTL shipments per workday increased 4.5%• LTL tonnage per workday increased 8.3%• LTL revenue per hundredweight, excluding fuel surcharge revenue, decreased 2.3%• LTL revenue per shipment, excluding fuel surcharge revenue, increased 1.3% • Full-Year Highlights • Revenue was $3.2 billion, an 11.4% increase• Operating income was $482.2 million, a 4.7% increase• Operating ratio of 85.0% compared to 84.0%• LTL shipments per workday increased 11.5%• LTL tonnage per workday increased 8.0%• LTL revenue per hundredweight, excluding fuel surcharge revenue, increased 4.3%• LTL revenue per shipment, excluding fuel surcharge revenue, increased 1.1% SAIA shares popped $12.98, or 2.7%, to $493.09.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


